Epidemiological and clinical characteristics of legionellosis in Northern Australia, 2010–2021

Claire Waller, Kevin Freeman, Shereen Labib, Rob Baird

# Abstract

## Objective

This study describes characteristics of the legionellosis cases occurring between 2010 and 2021 in the Northern Territory (NT), Australia.

## Methods

We retrospectively reviewed 53 cases of legionellosis during the defined period and documented patient and clinical characteristics, diagnostics, and seasonality of infection.

## Results

All cases were sporadic. The incidence rate in the NT was higher than the Australian median rate (2.1 and 1.5 per 100,000 population per year respectively). Aboriginal and Torres Strait Islander patients presented at a younger age than did non-Indigenous patients (median 41 and 60 years of age respectively), and overall there was a male preponderance. There was a higher proportion of legionellosis in the months with increased humidity, with a greater number of L. longbeachae infections detected overall (59%) than of L. pneumophila (41%). The majority of cases were diagnosed serologically (57% of L. pneumophilia and 93% of L. longbeachae ).

## Conclusions

Legionellosis in the NT is more common, seasonal, and may be underreported due to current reliance on serological testing for diagnosis. The higher incidence of legionellosis, and the younger age of Aboriginal and Torres Strait Islander patients of the NT, have public health implications, given that the clinical presentation of legionellosis is indistinguishable from other forms of pneumonia.

Keywords: Legionella, legionellosis, Northern Territory

# Introduction

Legionella bacteria are a group of gram-negative aerobic bacteria which are widespread in the environment. 1 Although more than 90 different species of Legionella have been reported, the most common pathogenic species in Australia are Legionella pneumophila and L. longbeachae which together account for 99% of notified cases. 2,3 Legionella spp. are known as opportunistic pathogens which can cause an acute pneumonic illness in susceptible hosts (Legionnaire’s disease) that cannot be distinguished clinically from other forms of pneumonia.1 Infection can also cause a milder, flu-like illness known as Pontiac fever.1 Although legionellosis can occur in previously healthy individuals, host risk factors are those which reduce local or systemic cellular immunity or which increase the chances of exposure to the bacteria.1 Specific risk factors include male gender; cigarette smoking; chronic heart or pulmonary disease; diabetes; end stage renal failure; age greater than 50 years; and immunosuppression.4

In the environment, Legionella spp. can be found associated with natural aqueous environments and soil, and have also been isolated from man-made systems such as hot and warm water systems; evaporative cooling towers; respiratory therapy devices; shower heads; and potting mixes.1,5 Legionella spp. are acquired via airborne transmission, involving inhalation of Legionella -containing aerosols and dust or micro aspiration of contaminated water.1,4

Legionellosis is notifiable in Australia and occurs both sporadically and in clusters or outbreaks. In a prospective, multicentre study of community-acquired pneumonia across Australia, Legionella spp. were identified as the causative pathogen in 3.4% of cases; however, this was based predominantly in temperate and urban regions of Australia. 6 Underreporting of legionellosis is also common because many sporadic cases are treated empirically without diagnostic testing being performed.

The objective of surveillance for legionellosis in Australia is to identify common sources of infection, especially in relation to clusters and outbreaks, to enable environmental investigation and instigation of control measures. Surveillance is also important to monitor the epidemiology of legionellosis in order to inform better preventative measures.

This report describes the profile, from January 2010 to April 2021, of legionellosis cases in the Northern Territory (NT), encompassing a diverse tropical and arid geographical region comprising rural and remote areas. In addition, Aboriginal and Torres Strait Islander people comprise one quarter of the population (25.5%).7

# Methods

Patients with legionellosis in the NT, from January 2010 to April 2021, were identified retrospectively, based on the NT Centre for Disease Control (CDC) National Notifiable Disease Database (NNDS) and through laboratory records. These patients were then cross-checked using the centralised laboratory Labtrak database (Intersystems, Cambridge), in addition to results being verified from the state referral laboratory, Westerns (Perth WA). Four additional cases that were not notified were identified through cross-checking with laboratory data.

Testing for legionellosis in the NT is routinely performed on all respiratory presentations to the intensive care unit (ICU), but is not always performed on respiratory presentations to the general wards unless requested by the treating clinician. The specific testing performed is at the discretion of the treating clinician. This usually includes urinary antigen and serology for ward-based respiratory inpatients, in addition to respiratory nasopharyngeal polymerase chain reaction (PCR) testing in ICU or high-risk inpatients.

Cases for inclusion were based on the Australian Government Department of Health legionellosis case definition, with both confirmed and probable cases notified in the NT and investigated. 8 A confirmed case of legionellosis had the following: laboratory definitive evidence AND clinical evidence, comprising 1) isolation of Legionella OR detection of Legionella urinary antigen OR seroconversion OR significant increase in antibody level OR a fourfold or greater rise to Legionella , AND 2) fever OR cough OR pneumonia. A probable case had the following: suggestive laboratory criteria AND clinical evidence, comprising 1) single high titre to Legionella OR detection of Legionella by nucleic acid testing (NAAT) OR detection of Legionella by direct fluorescence assay AND 2) fever AND cough OR pneumonia.

As per the Communicable Diseases Network Australia (CDNA) Legionellosis National Guidelines for Public Health Units, a cluster was defined as two or more cases, linked by area or residence or work, which have sufficient proximity in dates of onset of illness to warrant further investigation. 9 An outbreak was defined as two or more cases where the onset of illness is closely linked in time and where there is epidemiological evidence of a common source of infection.9

Serology was tested using an immunofluorescent assay (IFA); a four-fold rise in antibody titre after three to six weeks is predictive of legionellosis.10 L. pneumophila serogroup 1 urinary antigen testing was performed through BinaxNOW™ in vitro rapid immunochromatographic assay. The peak of urinary antigen detection for L. pneumophila is found at 5–10 days after onset of symptoms.10 Respiratory Legionella NAAT was performed by standard methods at accredited reference laboratories and included PCR for L. pneumophila and L. longbeachae but not pan-Legionella PCR. Culture was not performed.

The NT comprises two distinct geographical zones. The Top End of the Northern Territory (TENT) encompasses the northernmost section of Australia covering an area in excess of 500,000 km 2 with a sparse population of 180,000 and a distinct tropical monsoonal season. The TENT includes the regions of Darwin urban, Litchfield, Daly-Tiwi-West Arnhem, East Arnhem and Katherine. The rest of the NT is arid and sparsely populated and encompasses 700,000 km 2 and includes all other regions outside the TENT. The annualised disease incidence was calculated using the NT population data from the 2016 Australian Bureau of Statistics Census which included a population of 228,833 people, of whom one quarter (25.5%) identified as Aboriginal and/or Torres Strait Islander people (58,248 people). 7 The median age of the NT population is 32 years, which is younger than the median age for the rest of Australia (38 years). 7 Areas outside the urban centres of Greater Darwin (Darwin city, Darwin suburbs and Palmerston) were considered rural and remote, with approximately 40% of the NT population residing in rural or remote areas. 7 Incidence rate calculation and descriptive analysis were performed using Microsoft Excel. Categorical variables were analysed with the two-tailed Fisher’s exact test using SPSS (IBM SPSS Statistics for Windows, version 25.0). The study was approved by the Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research (Human Research Ethics Committee 2021-3998).


# Results

Over the 11-year study period there were 53 patients with legionellosis; two of these cases could not be speciated. All of the cases in the NT were sporadic; there were no clusters or outbreaks. Eighteen of these were confirmed cases and 35 were probable cases based on the Australian Government Department of Health legionellosis case definition. The overall annual infection incidence was 2.1 per 100,000 population per year. The incidence rate was higher among Aboriginal and Torres Strait Islander people (2.5 per 100,000 population per year) than among non-Indigenous people (2.0 per 100,000 population per year). There was overall a higher number of legionellosis cases (38/46, 83%) in the months associated with increased humidity in the TENT, which includes the wet season ‘build-up’ (September–December: 16/46, 35%) and monsoon (January–April: 22/46, 48%) (Figure 1).

All of the patients had a clinical presentation of pneumonia; there were no patients with Pontiac fever. Of the 53 cases, the median age was 54 years (interquartile range, IQR: 41–67), with a younger cohort found in Aboriginal and Torres Strait Islander patients (median age 41 years) than among non-Indigenous patients (median age 60 years), p < 0.01 (Table 1). There was a male preponderance (37/53, 70%). There was no significant difference in incidence rate between urban or rural and remote residence, when accounting for the NT population geographic distribution.

Of the 51 cases that could be identified by species, there was a higher proportion of L. longbeachae 30/51; 59%) than of L. pneumophila (21/51; 41 %) (p = 0.21). These epidemiological data are presented in Table 2. Cases due to L. longbeachae were identified more frequently in the wet season ‘build-up’ (14/30; 47%) than were cases due to L. pneumophila (4/21; 19%) (p = 0.073); similar numbers of each species were detected in the monsoonal and dry seasons. Patients with L. longbeachae infection had documented underlying lung disease more commonly (15/27; 56%) than did those with L. pneumophila (4/20; 20%). Smoking status was recorded for 13/21 (62%) L. pneumophila and 17/30 (57%) L. longbeachae cases, with 10/13 (77%) L. pneumophila and 11/17 (65%) L. longbeachae patients active or ex-smokers. Similar rates of other comorbidities between the two groups were observed (Table 3), with 15/20 (75%) L. pneumophila and 22/27 (81%) L. longbeachae cases identified as having concurrent chronic medical conditions. The majority of patients in this study were hospitalised (42/45; 93%), with similar rates of hospitalisation between the two group based on species: 18/20 (90%) of L. pneumophila cases and 24/25 (96%) of L. longbeachae cases. A greater proportion of patients in the L. longbeachae group (9/25; 36%) required admission to ICU than did those in the L. pneumophila group (4/20; 20%) (p = 0.327).

****Figure 1: NT Legionella cases and humidity by month, January 2010 to April 2021****



# Diagnostics

Overall, of the probable cases, 3/35 (9%) were determined as probable based on detection through NAAT alone and 32/35 (91%) ( p = 0.55) were classified based on a single high antibody titre. Fifty-seven percent of L. pneumophila patients (12/21) and 93% of L. longbeachae patients (28/30) were diagnosed serologically. Of the patients who underwent serological testing, the majority were diagnosed based on acute serology, with 10/12 L. pneumophila patients (83%) and 19/28 L. longbeachae patients (68%) having positive acute serology. Serological titres ranged from 1:64 to 1:>16384 for L. pneumophilia and from 1:64 to 1:2048 for L. longbeachae. NAAT was more frequently positive in patients with L. pneumophilia (4/5; 80%) than those with L. longbeachae (3/6; 50%) (p = 0.545), and was the sole method of diagnosis in 1/5 (20%) L. pneumophilia and 2/6 (33%) L. longbeachae patients. Urinary antigen was positive for L. pneumophila in 8/16 (50%) of those who were tested, and was the sole diagnostic means in 5/8 (63%) patients. Three patients with positive urinary antigen had concurrent positive NAAT on respiratory specimen (3/8; 37%).

This study was not designed to evaluate clinical management and therefore data on treatment were not obtained. Standard empiric treatment for Legionnaire’s disease in the NT follows national recommendations and includes azithromycin for low-moderate severity pneumonia (three to seven days) or doxycycline (ten to fourteen days) and for patients with high severity disease, azithromycin for seven to ten days.11

****Table 1: Demographics of patients with *Legionella* infection in the NT from January 2010 to April 2021****

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameter | Aboriginal and/or Torres Strait Islander (% of total) | Non-Indigenous (% of total) | Total (%) | *p* value |
| Number | 16 (30) | 37 (70) | 53 (100) |  |
| Median age in years (IQR) | 41 (39–54) | 60 (50–70) | 54 (41–67) | 0.01 |
| **Sex** | | | | |
| Male | 10 (63) | 27 (73) | 37 (70) |  |
| Female | 6 (37) | 10 (27) | 16 (30) |  |
| **Residence** | | | | |
| Urban | 7 (44) | 30 (81) | 37 (70) |  |
| Rural and remote | 9 (56) | 7 (19) | 16 (30) |  |
| **Comorbiditiesa** | | | | |
| Lung disease | 7 (44) | 11 (34) | 18 (38) |  |
| Other health conditions | 10 (63) | 25 (78) | 35 (73) |  |
| **Seasonality of infectionb** | | | | |
| Monsoon | 7 (44) | 18 (49) | 25 (47) |  |
| Dry | 3 (19) | 7 (19) | 10 (19) |  |
| Wet season ‘build-up’ | 6 (38) | 12 (32) | 18 (34) |  |

a Comorbidities were recorded for 16/16 Aboriginal and/or Torres Strait Islander patients and 32/37 non-Indigenous patients.

b In the Top End, the monsoon season spans the months January, February, March, April; the dry season spans the months of May, June, July, August; the wet season ‘build-up’ months are September, October, November and December.

****Table 2: Epidemiological features of patients with *Legionella* infection in the NT from January 2010 to April 2021****

|  |  |  |  |
| --- | --- | --- | --- |
| Parametera | *Legionella pneumophila* (%) | *Legionella longbeachae* (%) | Total (%) |
| Number | 21 (41) | 30 (59) | 51 (100) |
| Median age (IQR) | 56 (52–71) | 54 (41–65) | 54 (41–67) |
| **Sex** | | | |
| Male | 13 (62) | 23 (77) | 36 (71) |
| Female | 8 (38) | 7 (23) | 15 (29) |
| **Ethnicity** | | | |
| Aboriginal and/or Torres Strait Islander | 7 (33) | 9 (30) | 16 (31) |
| Non-Indigenous | 14 (67) | 21 (70) | 35 (69) |
| **Residence** | | | |
| Urban | 15 (71) | 20 (67) | 35 (69) |
| Rural and remote | 6 (29) | 10 (33) | 16 (31) |
| **Seasonality of infection** | | | |
| Monsoon | 11 (52) | 12 (40) | 23 (45) |
| Dry | 6 (29) | 4 (13) | 10 (20) |
| Wet season ‘build-up’ | 4 (19) | 14 (47) | 18 (35) |

a Two cases of *Legionella* infection did not speciate, and are not included in the table.

****Table 3: Clinical characteristics of patients with *Legionella* infection in the NT from January 2010 to April 2021****

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | *L. pneumophila* Number (%) | *L. longbeachae*  Number (%) | Total (%) |
| Number | 21 (44) | 30 (59) | 51 (100) |
| **Comorbiditiesa** | | | |
| Lung disease | 4 (20) | 15 (56) | 19 (40) |
| Other health conditions | 15 (75) | 22 (81) | 37 (79) |
| **Diagnosticb** |  |  |  |
| Acute serology | 10 (83) | 19 (68) | 29 (66) |
| Convalescent serology | 2 (17) | 9 (32) | 11 (41) |
| NAAT positive | 4 (80) | 3 (50) | 7 (64) |
| NAAT negative | 1 (20) | 3 (50) | 4 (36) |
| Urine antigen positive | 8 (50) | NAc |  |
| Urine antigen negative | 8 (50) | NAc |  |
| **Clinicald** |  |  |  |
| Hospitalised | 18 (90) | 24 (96) | 42 (93) |
| ICU admission | 4 (20) | 9 (36) | 13 (30) |
| Length of stay (days), median (IQR) | 6 (5–10) | 6 (4–44) |  |
| 30 day mortality | 1 (5) | 1 (4) | 2 (4) |

a Comorbidities available for 20/21 *L. pneumophila* and 27/30 *L. longbeachae* cases.

b Acute and convalescent serology performed on 16/21 and 11/21 *L. pneumophila* and 28/30 and 16/30 *L. longbeachae* cases respectively. Nucleic amplification tests (NAAT) performed on 5/21 *L. pneumophila* and 6/30 *L. longbeachae* cases.

c NA not applicable.

d Clinical information available on 20/21 *L. pneumophila* and 25/30 *L. longbeachae* cases.

# Discussion

Our study of legionellosis in the NT noted differences in the disease incidence when compared to overall incidence in Australia. Australia has a national incidence of legionella infection of 1.5 per 100,000 population per year. 3 The NT annualised rate over the 11 years of this study, of 2.1 per 100,000 population per year, is 40% higher than the national median incidence. Noting the relative youthfulness of the NT population (legionella infection classically occurs in the elderly), and the dry, arid conditions of the southern half of the NT ( Legionella prefers a moist environment), this has significant disease projection implications for future case numbers with an aging NT population. Legionellosis in Aboriginal and Torres Strait Islander persons, who comprise twenty-five percent of the NT population, showed a higher incidence than in non-Indigenous Territorians (2.5 versus 2.0 per 100,000 population per year respectively); the median age of occurrence was 19 years less in Aboriginal and Torres Strait Islander Territorians ( p < 0.01), which may reflect the known higher rates of health hardware issues in this population. 12 The male predominance of legionella infections (71%) in our cohort, and background rates of lung disease, smoking and comorbidities, are similar to previous studies in New Zealand and Australia. 3,5,13,14 Admission rates to ICU were higher in the NT (13/45; 30%) than in other studies which reported rates of ICU admission up to 16%; this may reflect diagnostic rigour in patients admitted to ICU, who are routinely tested for legionellosis if they have respiratory symptoms. 15 Thirty-day mortality was lower in the NT (2/45; 4%) than the national notified rate of 6%; however, this is within the margin of error for this small sample size. 3 These mortality rates are still lower than the rates reported internationally, with case fatality rates ranging between 8 and 12%; this may reflect differences in the environment and population characteristics as well as increased active case finding in Australasian countries. 16

## Seasonality in NT

Our data showed a trend towards cases occurring in the humid months. Internationally, a striking epidemiologic feature of **legionellosis** is its seasonality: more cases are reported during the summer. 3,16,17 However, strong evidence indicates that weather—particularly temperature and humidity—drives the summer spike in incidence. 17 Although  Legionella spp. are common in the environment, dry environments do not support them, 2 and  Legionella spp. are more sensitive than other pathogens to drying conditions. 1 In contrast, warm and humid weather tends to support pathogen survival, growth, and the potential for aerosol exposures, increasing disease risk. 1 Legionnaires’ disease caused by L. pneumophila is possibly more common in late summer and early autumn, 17 whereas that caused by L. longbeachae peaks in spring and early summer. 13 Most Legionella  spp., including L. pneumophila , mainly reside in bodies of water. Additional factors that promote growth in water include warm temperatures (25 to 42 °C). By contrast,  L. longbeachae is genetically adapted to invade plant material and primarily resides in soil and compost. 2 Among cases reported in the NT from January 2010 to April 2021, L. longbeachae was more common (30/51; 59%) than L. pneumophilia (21/51; 41%) . This may relate to the environmental conditions that promote survival of L. longbeachae.

## Diagnosis

The Northern Territory has access to three of the four methods of Legionella species diagnosis (culture not available), all of which are complementary. L. pneumophila urinary antigen was the diagnostic in 50% of patients, but is not available for other legionella species. L. longbeachae diagnosis was predominantly serological; however, with increasing use of multiplex respiratory NAAT testing, this may alter in the future. No one method meets the requires specificity and sensitivity and our data emphasises the need for a full diagnostic panel if legionella is being considered.

Of the 12 L. pneumophila cases diagnosed serologically, ten (83%) were diagnosed from acute sera samples, compared to the 28 L. longbeachae that were serologically diagnosed where only 19 (68%) of cases had positive acute serology, and nine patients (32%) subsequently seroconverted. As acute diagnostic specimens are generally taken on presentation to hospital, it may suggest that L. longbeachae is a more rapidly progressive infection, and more likely seronegative on acute presentation serology, compared to L. pneumophila with a higher (10/12, 83%) rate of diagnosis based on acute serology. However, these findings do emphasise the need for convalescent serology in all undiagnosed pneumonia cases, to improve diagnostic yield.

For three patients, PCR was the sole diagnostic means, but these were all listed as probable cases as PCR diagnosis is not yet defined as a confirmed case in the NNDSS definition but is included in the Public Health Laboratory Network (PHLN) laboratory confirmed definition. The experience in New Zealand 15,18 has shown that NAAT is much more effective at diagnosing legionellosis, in particular because serology is not rapidly available to guide clinical management and because a substantial proportion of patients (20–30%) do not develop detectable antibody response if tested too early in the disease process or at all. 19 Whilst urinary antigen in this study was shown to diagnose 50% of L. pneumophila cases (8/16), it is of less utility in the NT context when L. longbeachae is the predominant species. Harmonisation of notified and laboratory case definitions would aid in epidemiological research. Greater use of NAAT for diagnosis rather that serology may uncover an increased number of legionellosis cases, particularly L. longbeachae , which could allow preventative public health interventions, and more targeted antimicrobial therapy. This was evidenced in New Zealand when active case finding through systematic NAAT testing uncovered an otherwise hidden burden of disease, almost quadrupling the case finding during the period of the study. 18 Active case finding in New Zealand identified that the overall incidence in 20 participating hospitals was 5.4 per 100 000 people per year. 15

## Strengths and limitations

This study has a number of limitations. Firstly, it was a retrospective study, and may have missed cases that did not come through the public hospital system or pneumonic cases that did not have legionella diagnostics performed. Secondly, the diagnostic algorithms in place in the NT are heavily weighted towards diagnosing the common Australian species of L. pneumophila and L. longbeachae . Other species causing clinical disease may be missed as Legionella culture is not routinely performed nor pan- Legionella PCR. With the advent of multiplex respiratory PCR, addition of pan- Legionella PCR targets may help to characterise the full spectrum of legionellosis in the NT, and as per the New Zealand experience may increase case finding in pneumonia patients. Differences in the reporting definition and laboratory definition mentioned do not change this study’s overall conclusions. Finally, this study did not evaluate detailed clinical presentation or individual risk factors for Legionella species acquisition (specifically: individual exposures to soil or compost). It also did not evaluate treatment and management of legionellosis and how this influenced hospital length of stay and mortality.

# Conclusion

Legionnaire’s disease is a serious cause of pneumonia and has a high mortality rate, particularly if it is untreated or occurs in the immunocompromised. 20 The higher incidence of disease in the NT has public health implications, given that the population is younger and relatively dispersed, which has impacts on access to, and delivery of, healthcare. Reliance on serological testing and urinary antigen in this retrospective study, rather than NAAT detection, means that the true burden of disease may be significantly underreported. Improved clinical recognition and use of diagnostics will allow public health preventative interventions and targeted treatment, and has the potential to improve patient outcomes.

# Acknowledgements

The authors would like to thank Linda Ward from the Menzies School of Research for her assistance with statistical analysis.

# Author details

Claire Waller 1   
Kevin Freeman 1   
Shereen Labib 2   
Rob Baird 1

1. c/o Territory Pathology, Building 13, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT, 0810
2. Centre for Disease Control, Building 4, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT, 0810

## Corresponding author

Claire Waller

Infectious Diseases Registrar, Royal Darwin Hospital, 105 Rocklands Drive, Tiwi, NT, 0810

Email: Claire.Waller@nt.gov.au

# References

1. Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases (8th edition). Philadelphia: Churchill Livingstone Elsevier, 2014.
2. Chambers ST, Slow S, Scott-Thomas A, Murdoch DR. Legionellosis caused by non- Legionella pneumophila species, with a focus on Legionella longbeachae . Microorganisms . 2021;9(2). doi: https://doi.org/10.3390/microorganisms9020291.
3. NNDSS Annual Report Working Group. Australia’s notifiable diseases status 2014: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell Q Rep . 2016;40(1):E48–145.
4. Stout JE, Yu VL. Legionellosis. N Eng J Med . 1997;337(10):682–7.
5. Li, JS, O’Brien ED, Guest C. A review of national legionellosis surveillance in Australia, 1991–2000. Commun Dis Intell Q Rep . 2002;26(3):462–70.
6. Charles PGP, Whitby M, Fuller AJ, Stirling R, Wright AA, Korman TM et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis . 2008;46(10):1513–21.
7. Australian Bureau of Statistics. 2016 Census QuickStats: Northern Territory. [Webpage.] Canberra: Australian Government, Australian Bureau of Statistics; 2021. [Accessed on 12 June 2021.] Available from: https://quickstats.censusdata.abs.gov.au/census\_services/getproduct/census/2016/quickstat/7.
8. Australian Government Department of Health. Legionellosis case definition. [Internet.] Canberra: Australian Government Department of Health; 20 December 2012. [Accessed on 12 June 2021.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd\_legion.htm.
9. Australian Government Department of Health. Legionellosis: CDNA national guidelines for public health units. [Internet.] Canberra: Australian Government Department of Health; 10 October 2017. [Accessed on 10 July 2021.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-legionella.htm.
10. Australian Government Department of Health. Legionella Laboratory Case Definition (LCD). [Internet.] Canberra: Australian Government Department of Health; 16 August 2019. [Accessed on 1 June 2021.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-phlncd-legionella.htm.
11. Therapeutic Guidelines. eTG complete: Directed therapy for pneumonia: Legionella pneumonia in adults. [Webpage.] Melbourne: Therapeutic Guidelines Limited; March 2020. [Accessed on 1 June 2021.] Available from: https://tgldcdp.tg.org.au/viewTopic?topicfile=pneumonia-directed-therapy&guidelineName=Antibiotic#toc\_d1e645.
12. Torzillo PJ, Pholeros P, Rainow S, Barker G, Sowerbutts T, Short T et al. The state of health hardware in Aboriginal communities in rural and remote Australia. Aust N Z J Public Health . 2008;32(1):7–11.
13. Isenman HL, Chambers ST, Pithe AD, Macdonald SLS, Hegarty JM, Fenwick JL et al. Legionnaire’s disease caused by Legionella longbeachae : clinical features and outcomes of 107 cases from an endemic area. Respirology . 2016;21(7):1292–9.
14. Cameron S, Roder D, Walker C, Feldheim J. Epidemiological characteristics of Legionella infection in South Australia: implications for disease control. Aust N Z J Med . 1991;21(1):65–70.
15. Priest PC, Slow S, Chambers ST, Cameron CM, Balm MN, Beale MW et al. The burden of Legionnaires’ disease in New Zealand (LegiNZ): a national surveillance study. Lancet Infect Dis . 2019;19(7):770–7.
16. Phin N, Parry-Ford-F, Harrison T, Stagg H, Zhang N, Kumar K et al. Epidemiology and clinical management of Legionnaires’ disease. Lancet Infec Dis . 2014;14(10):1011–21.
17. Simmering JE, Polgreen LA, Hornick DB, Sewekk DK, Polgreen PM. Weather dependent risk for Legionnaires’ disease, United States. Emerg Infect Dis . 2017;23(11):1843–51.
18. Murdoch DR, Podmore RG, Anderson TP, Barratt K, Maze MJ, French KE et al. Impact of routine systematic polymerase chain reaction testing on case finding for Legionnaires’ disease: a pre-post comparison study. Clin Inf Dis . 2013;57(9):1275–81.
19. Anvi T, Beiber A, Green H, Steinmetz T, Leibovici L, Paul M. Diagnostic accuracy of PCR alone and compared to urinary antigen testing for detection of Legionella spp.: a systematic review. J Clin Microbiol . 2016;54(2):401–11.
20. Kenagy E, Priest PC, Cameron CM, Smith D, Scott P, Cho V et al. Risk factors for Legionella longbeachae Legionnaire’s disease, New Zealand. Emerg Infect Dis . 2017;23(7):1148–54.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection and Response, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Noel Lally

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**CDI is produced by the Office of Health Protection and Response, Australian Government Department of Health, GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2022 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>